Your shopping cart is currently empty

CITCO inhibits growth and expansion of brain tumour stem cells (BTSCs) and has an EC50 of 49 nM over pregnane X receptor (PXR), and no activity on other nuclear receptors. CITCO is an imidazothiazole derivative and it also is a selective Constitutive androstane receptor (CAR) agonist.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $57 | In Stock | In Stock | |
| 10 mg | $91 | In Stock | In Stock | |
| 25 mg | $166 | In Stock | In Stock | |
| 50 mg | $266 | In Stock | In Stock | |
| 100 mg | $397 | In Stock | In Stock | |
| 200 mg | $597 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $63 | In Stock | In Stock |
| Description | CITCO inhibits growth and expansion of brain tumour stem cells (BTSCs) and has an EC50 of 49 nM over pregnane X receptor (PXR), and no activity on other nuclear receptors. CITCO is an imidazothiazole derivative and it also is a selective Constitutive androstane receptor (CAR) agonist. |
| In vitro | CITCO (1-50 μM; 48 hours) results in dose-dependent inhibition of viable cell count and proliferation in T98G, U87MG glioma, and BTSCs. CITCO (0-25 μM; 48 hours) significantly increases CAR protein expression in T98G, U87MG glioma, and BTSCs. CITCO (2.5-10 μM; 48 hours) induces apoptosis in BTSCs in a dose-dependent manner, but not in normal astrocytes. CITCO (2.5, 5 μM; 48 hours) induces differential cell cycle arrest in various BTSCs in culture, but not in normal astrocytes[1]. |
| In vivo | CITCO (intraperitoneal; 25?μg; on days 22, 24, 26, 30 and 36) results a significant decrease in tumour growth. After treatment with 100?μg CITCO, it further decreases to an undetectable level [1]. |
| Molecular Weight | 436.74 |
| Formula | C19H12Cl3N3OS |
| Cas No. | 338404-52-7 |
| Smiles | C(=NOCC1=CC(Cl)=C(Cl)C=C1)C2=C(N=C3N2C=CS3)C4=CC=C(Cl)C=C4 |
| Relative Density. | 1.48g/cm3 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | H2O: insoluble DMSO: 20.8 mg/mL (47.63 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 1 mg/mL (2.29 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.